41 results about "Eosinophilic Granulocyte" patented technology

The application discloses application of volatile oil of Citrus aurantium in preparation of a medicine for preventing and treating allergic rhinitis. The application proposes that the volatile oil of Citrus aurantium can significantly reduce the levels of mast cell factors IL-1beta and TNF-alpha, and can also significantly reduce the levels of inflammatory factors IL-13 and IL-4 in mice, reduce inflammatory cell infiltration, and reduce eosinophilic granulocyte increase and gland hyperplasia. The application proposes that the volatile oil of Citrus aurantium has great potential as a medicinal and edible raw material for treating allergic rhinitis. The application also proposes that the volatile oil of Citrus aurantium can significantly improve symptoms such as sneezing, runny nose, and nasal itching of mice caused by allergic rhinitis, and the symptoms seriously affect the life of patients.

The invention discloses an application of thermal sensitive Sibestein granules in treating / or preventing asthma, and belongs to the technical field of biological medicines. The invention finds that the thermal sensitive Sibestein granules can reduce the total number of cells and the number of eosinophilic granulocytes, neutrophil granulocytes and lymphocytes in asthma mice BALF, reduce the level of cell factors in asthma mice BALF and IgE in serum, reduce exudation of inflammatory substances in airway and alveolar tissues of asthma mice and infiltration of inflammatory cells, improve the lesion degree of lung tissues, and improve the curative effect of the lung tissues. The action mechanism may be related to regulation and control of MAPK / NF-kappa B signal channel related protein expression, so that inflammatory response and cell apoptosis are inhibited, and airway inflammation of mice is relieved.

The invention relates to the technical field of compositions, and particularly discloses a composition for assisting in improving eosinophilic esophagitis and application of the composition. The composition for assisting in improving eosinophilic esophagitis provided by the invention comprises an iron source, a zinc source and L-carnitine. By optimizing the components of the composition and specifically limiting the proportion of the iron source, the zinc source and the L-carnitine in the composition, esophageal epithelial hyperplasia can be effectively reversed, the number of bifidobacteria is increased, the number of enterobacter and esophageal tissue eosinophilic granulocytes is reduced, the level of IL-13 cell factors is reduced, and the curative effect is improved. Further, the effect of remarkably assisting in improving eosinophilic granulocytic esophagitis is achieved.

The invention discloses an immune-engineered mitochondrial nMITO as well as a preparation method, application and an evaluation method thereof, and relates to the technical field of asthma treatment. According to the application of the immune-engineered mitochondrial nMITO in preparation of the medicine for treating asthma, through the specific immune regulation function of the nMITO, local overactivated immune cells (such as eosinophilic granulocytes and Th2 cells) of an airway are regulated in a targeted mode, abnormal release of proinflammatory factors (such as IL-4, IL-5 and IL-13) is inhibited, meanwhile, activation of an anti-inflammatory signal channel is promoted, and the anti-inflammatory effect is improved. Therefore, the steady state of the airway immune microenvironment is recovered, accurate and efficient intervention on chronic asthma inflammation is achieved, the aims of improving the treatment effect, reducing adverse reactions and reducing disease relapse are finally achieved, and a brand new technical scheme is provided for clinical treatment of asthma.

The invention provides a method for detecting eosinophilic granulocyte peroxidase and application thereof, and relates to the technical field of biological detection.The method comprises the steps that a respiratory tract sample and a sample treatment reagent are mixed, dispersion treatment and centrifugation are conducted, supernatant is taken, and a to-be-detected sample is obtained; carrying out magnetic particle chemiluminescence detection on a to-be-detected sample, and judging the content of eosinophilic granulocyte peroxidase according to a luminescence signal value obtained by detection, the final pH value of the reaction system is 8.0-12.0 according to the detection of a light-emitting signal value; the sample treatment reagent is an aqueous solution containing 0.06-0.12% w / v of a reducing agent. The technical prejudice that the EPX detection is interfered by the peroxidase activity of the EPX in the prior art is overcome; and meanwhile, the mucus is uniformly dispersed through dispersion treatment by virtue of a sample treatment reagent containing a reducing agent, so that high-sensitivity and high-specificity full-automatic detection of the respiratory tract sample EPX is realized on the magnetic particle chemiluminescence platform for the first time.

The invention belongs to the field of biological medicine, and relates to an anti-IL-5 antibody, and a pharmaceutical composition and application thereof. Specifically, the invention relates to an anti-IL-5 antibody or an antigen binding fragment thereof, the anti-IL-5 antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises complementarity determining regions HCDR1 to HCDR3, the light chain variable region comprises complementarity determining regions LCDR1 to LCDR3, the amino acid sequence of the HCDR1 is shown as SEQ ID NO: 3, the amino acid sequence of the HCDR2 is shown as SEQ ID NO: 4, and the amino acid sequence of the HCDR3 is shown as SEQ ID NO: 5, the amino acid sequence of the LCDR1 is as shown in SEQ ID NO: 6, the amino acid sequence of the LCDR2 is as shown in SEQ ID NO: 7, and the amino acid sequence of the LCDR3 is as shown in SEQ ID NO: 8. The antibody disclosed by the invention can be specifically combined with IL-5, has relatively high affinity, and has good potential for treating or preventing diseases caused by eosinophilic granulocytes higher than normal level.

The present invention provides an antibody or a conjugated fragment of a citrulline-containing epitope used for the treatment or prevention of diseases associated with the release of extracellular traps from cells, such as neutrophil extracellular trap (NET)-associated pathology (NET-associated pathology) or eosinophil extracellular trap (EET)-associated pathology (EET-associated pathology), and provides a method comprising administering at least one dose of the antibody at a specific concentration. The present invention also provides the method itself. NET-related pathologies include systemic lupus erythematosus (SLE), lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus exacerbated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, or wound healing in diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in This includes other NET-related pathologies, such as the health of transplanted organs in vivo or ex vivo.The present invention also relates to wound healing in SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid antibody syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia asthma, allergic rhinovirus exacerbating asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, or diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in vivo or ex vivo The present invention provides pharmaceutical compositions and methods for treating and preventing NET-related pathologies, including other NET-related pathologies such as the health of transplanted organs in vivo. NET-related pathologies include eosinophilic diseases or conditions of the skin, respiratory eosinophilic diseases or conditions, gastrointestinal eosinophilic diseases or conditions, allergic diseases or conditions, or eosinophilic diseases or conditions such as helminthic, fungal, viral or bacterial infections.

The invention relates to the technical field of probiotics, in particular to an application of a probiotic (Bifidobacterium longum) in allergic asthma (preventing, relieving or treating allergic asthma). The invention relates to an application of probiotics in allergic asthma, in particular to an application of the probiotics in inhibiting a PI3K / AKT / NF-kappa B signal channel. According to the probiotics disclosed by the invention, activation of a PI3K / AKT / NF-kappa B signal channel is specifically inhibited, immune imbalance is regulated and controlled from the source, and Th2 type immune response is effectively inhibited. Specifically, the total IgE level in serum and the expression of Th2 type cytokines such as IL-4, IL-5 and IL-13 are remarkably reduced, the inflammatory response of the airway mainly caused by eosinophilic granulocyte infiltration is relieved, and the airway high reactivity and airway remodeling are effectively improved. The invention provides a novel intervention strategy which is clear in mechanism, high in safety and capable of treating both symptoms and root causes according to the intestine-lung axis theory, and has a wide application prospect in the aspect of treating allergic asthma.

The present invention provides an antibody comprising citrulline epitope or a binding fragment thereof for use in the treatment or prevention of a disease associated with release of an extracellular trap from a cell, such as a neutrophil extracellular trap (NET)-associated disease (NET-associated disease) or an eosinophil extracellular trap (EET)-associated disease (EET-associated disease), the method comprises administering at least one dose of an antibody at a specific concentration. The present invention also provides these methods themselves. NET related diseases include systemic lupus erythematosus (SLE), lupus, septicemia, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), sicca syndrome, antiphospholipid syndrome, Behcet's disease, spondylitis, spondyloarthropathy, multi-system atrophy, and the like. Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus aggravated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulogenic uveitis, granulogenic uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, and the like. Or other NET-related diseases, such as wound healing in diabetic patients, cancer, cancer metastasis, and transplanted organ health in vivo or in vitro. The invention also provides a pharmaceutical composition and a method for treating or preventing NET related diseases. Such as SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), sicca syndrome, antiphospholipid syndrome, Behcet's disease, spondylitis, spondyloarthropathy, multi-system atrophy, Parkinson's disease, Lewy body dementia, asthma, and the like. Allergic rhinovirus aggravated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulometric uveitis, granulometric uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, and the like. Or other NET-related diseases, such as wound healing in diabetic patients, cancer, cancer metastasis, and transplanted organ health in vivo or in vitro. The EET-related diseases include eosinophilic granulocyte diseases or conditions, such as eosinophilic granulocyte diseases or conditions of skin; a respiratory eosinophilic granulocyte disease or condition; gastrointestinal eosinophilic cell diseases or disorders; allergic diseases or conditions; or worm, fungus, virus or bacterial infection.

The invention belongs to the technical field of biomedicine, and discloses an antibody for evaluating the curative effect of infantile pneumonia asthma and application of the antibody. The heavy chain CDR sequence of the monoclonal antibody (secreted by the hybridoma cell strain 2B5) is SEQ ID NO: 2-4, the light chain CDR sequence of the monoclonal antibody (secreted by the hybridoma cell strain 2B5) is SEQ ID NO: 6-8, the dissociation constant of the monoclonal antibody and an IL-5R antigen reaches 2.435 * 10 <-1 > / L, and the affinity is high. The antibody can accurately evaluate the curative effect of infantile pneumonia and asthma by detecting the lung function, the ratio of eosinophilic granulocytes in bronchoalveolar lavage fluid and lung tissue inflammation, can also significantly improve airway obstruction and inflammation of asthma model mice, has an effect superior to that of dexamethasone, solves the problems that existing curative effect evaluation is lack of specific tools and has large side effects of therapeutic drugs, and has good clinical application prospects. And a new scheme is provided for curative effect evaluation and adjuvant therapy of infantile pneumonia asthma.

The invention discloses an ABPA animal model building method which comprises the following steps: building an ABPA animal model by injecting a live aspergillus fumigatus spore suspension into an airway, and selecting a mouse for adaptive feeding; a primary sensitization stage; repeating the excitation stage; a live aspergillus fumigatus spore colonization excitation stage; and establishing an evaluation model. The animal model which highly simulates the pathophysiological characteristics of human ABPA is constructed by performing sensitization and excitation in stages and in multiple modes, especially by introducing the key step of lung colonization of live aspergillus fumigatus spores; through increase of serum total IgE and aspergillus fumigatus specific IgE levels, airway eosinophilic granulocyte infiltration and high secretion of mucus, the evaluation model is successfully constructed, and a reliable experimental platform is provided for deep analysis of pathogenesis of diseases.

The present invention belongs to the field of biomedicine, and relates to an anti-IL-5 antibody, a pharmaceutical composition thereof and the use thereof. Specifically, the present invention relates to an anti-IL-5 antibody or an antigen-binding fragment thereof. The anti-IL-5 antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises complementary determining regions HCDR1-HCDR3, and the light chain variable region comprises complementary determining regions LCDR1-LCDR3, wherein an amino acid sequence of HCDR1 is set forth in SEQ ID NO: 3, an amino acid sequence of HCDR2 is set forth in SEQ ID NO: 4, and an amino acid sequence of HCDR3 is set forth in SEQ ID NO: 5; and an amino acid sequence of LCDR1 is set forth in SEQ ID NO: 6, an amino acid sequence of LCDR2 is set forth in SEQ ID NO: 7, and an amino acid sequence of LCDR3 is set forth in SEQ ID NO: 8. The antibody of the present invention can specifically bind to IL-5, exhibits a high affinity, and has a good potential for treating or preventing diseases caused by eosinophils above the normal level.

The embodiment of the invention relates to a sample analyzer and a sample analysis method. The sample analysis method comprises the following steps: sucking a to-be-detected blood sample; mixing at least one part of the blood sample to be tested, the hemolytic agent, the first dye and the second dye to prepare a test sample; in a single test, the particles in the measurement sample pass through the optical detection area irradiated by the excitation light one by one to obtain optical information. The optical information includes scattered light information, first fluorescence information, and second fluorescence information. The result of counting a neutrophil population, the result of counting a lymphocyte population, the result of counting a monocyte population, the result of counting an eosinophil population, and the result of counting a basophil population in the measurement sample are acquired on the basis of the at least one type of scattered light information and the first fluorescence information. And correcting the counting result of the basophilic granulocyte population based on at least the second fluorescence information, thereby obtaining an accurate counting result of the basophilic granulocyte population.

Described herein are mucoadhesive pharmaceutical compositions of corticosteroids, as well as methods of making such pharmaceutical compositions, and therapeutic methods using them. The compositions typically comprise a corticosteroid in a mucoadhesive system, wherein the mucoadhesive system comprises a rheology-modifying agent and a vehicle for the corticosteroid. The compositions are particularly useful for treating inflammatory conditions of the esophagus, such as eosinophilic esophagitis, or inflammatory bowel disease.

The invention relates to a biomarker for distinguishing depression and bipolar affective disorder and application thereof, in particular to a composition for distinguishing depression and bipolar affective disorder, a method for providing information for distinguishing depression and bipolar affective disorder through the composition and the like, and the composition comprises a preparation. The preparation detects the expression level of each of six proteins of a biomarker based on a biomarker composition for distinguishing depression from bipolar affective disorder, and the biomarker composition comprises an eosinophilic granulocyte chemokine (Eotaxin), a nerve growth factor (NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF and NGF in a serum sample. The invention relates to a tumor necrosis factor-alpha (tumor necrosis factor-alpha, TNF-alpha), a glial cell derived neurotrophic factor (GDNF), an interleukin-1beta (interleukin-1beta, IL-1beta), and a serum soluble CD40 ligand (sCD40L), in particular to a tumor necrosis factor-alpha (tumor necrosis factor-alpha, TNF-alpha), a glial cell derived neurotrophic factor (GDNF), an interleukin-1beta (interleukin-1beta, IL-1beta), a tumor necrosis factor-alpha (tumor necrosis factor-alpha, TNF-alpha) and a serum soluble CD40 ligand (sCD40L).

The present application relates to the technical field of artificial intelligence, and provides a system and method for classifying eosinophilic gastroenteritis based on multi-modal data, which comprises: obtaining digestive endoscopy images, ultrasonic endoscopy images, CT examination images and clinical manifestation data collected by a subject in the same period; identifying the state of gastrointestinal mucosa lesions and representing the numerical characteristics through the digestive endoscopy images; identifying the abnormal thickening of each membrane layer structure of the gastrointestinal wall and representing the numerical characteristics through the ultrasonic endoscopy images; determining the lesion level distribution and representing the numerical characteristics through the ultrasonic endoscopy images; determining the peritoneal effusion and intestinal wall thickening and representing the numerical characteristics through the CT examination images; obtaining the clinical symptom characteristics and representing the numerical characteristics through the clinical manifestation data; generating a feature vector based on multi-modal data by representing each numerical characteristic; and inputting the feature vector into a dynamic classification prediction model to realize the classification prediction of eosinophilic gastroenteritis, thereby improving the accuracy of auxiliary diagnosis and evaluation.

The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.

The present disclosure provides a kind of chimeric antigen receptor, recombinant immune cell and use.The present application provides a kind of recombinant immune cell, wherein the recombinant immune cell includes: (i) one or more structures for cell adoptive therapy;(ii) the gene regulation system capable of reducing or eliminating the expression and / or function of BCOR gene and ZC3H12A gene in immune cells;Wherein, the structure for cell adoptive therapy specifically binds to the antigen derived from eosinophil.The recombinant immune cell provided by the present application avoids the use of pretreatment with great toxic side effects;Target cells can be effectively eliminated for a long time, and a single treatment can achieve the effect of prevention and long-term cure.And these long-term existing recombinant immune cells in vivo can also act as carriers to secrete proteins with therapeutic effects, including antibodies, polypeptides and hormones, etc.

The present application relates to the field of biotechnology and in vitro diagnosis, in particular to a monoclonal antibody against eosinophil peroxidase and its application. The antibody of the present application can directly and specifically capture the eosinophil peroxidase with enzymatic activity, and is used in biological research and clinical diagnosis of eosinophils. The monoclonal antibody against eosinophil peroxidase of the present application is prepared by immunizing Balb / c mice with recombinant eosinophil peroxidase as an immunogen, then fusing the spleen with myeloma cells NS1, and screening and purifying. The prepared monoclonal antibody against eosinophil peroxidase specifically recognizes the epitope of eosinophil peroxidase.

The present application belongs to the technical field of biological medicine, and particularly relates to a pyruvate preparation for asthma treatment and a preparation method thereof. The pyruvate preparation comprises the following components in parts by weight: 10-12 parts of pyruvate, 10-12 parts of sodium chloride, 0.5-1 part of citric acid, and 500 parts of water for injection; and the pH of the pyruvate preparation is 6-7. The pyruvate preparation is used for daily management of asthma patients, can control the increase of inflammatory cells such as eosinophilic granulocyte, reduce inflammatory reaction, and thus achieve the purpose of inhibiting asthma. The effect of the pyruvate preparation is close to that of the same kind of hormone drug dexamethasone, and the pyruvate preparation can achieve the treatment purpose while reducing the dependence of patients on hormone drugs and side effects.

The present invention belongs to the field of biomedicine, and relates to an anti-IL-5 antibody, a pharmaceutical composition thereof and the use thereof. Specifically, the present invention relates to an anti-IL-5 antibody or an antigen-binding fragment thereof. The anti-IL-5 antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises complementary determining regions HCDR1-HCDR3, and the light chain variable region comprises complementary determining regions LCDR1-LCDR3, wherein an amino acid sequence of HCDR1 is set forth in SEQ ID NO: 3, an amino acid sequence of HCDR2 is set forth in SEQ ID NO: 4, and an amino acid sequence of HCDR3 is set forth in SEQ ID NO: 5; and an amino acid sequence of LCDR1 is set forth in SEQ ID NO: 6, an amino acid sequence of LCDR2 is set forth in SEQ ID NO: 7, and an amino acid sequence of LCDR3 is set forth in SEQ ID NO: 8. The antibody of the present invention can specifically bind to IL-5, exhibits a high affinity, and has a good potential for treating or preventing diseases caused by eosinophils above the normal level.

The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.

The invention provides a method for treating hepatocellular carcinoma (HCC) by utilizing cytokines to recruit eosinophilic granulocytes. According to the invention, single sample gene set enrichment analysis (ssGSEA) is adopted to calculate a hepatocellular carcinoma immune infiltration score, and eosinophilic granulocyte infiltration is screened out, so that the lifetime of an HCC patient can be prolonged. Experiments prove that by collecting eosinophilic granulocytes through cytokines, activation and proliferation of NK cells, CD8 T cells and CD4 T cells in the liver can be directly or indirectly promoted, and secretion of IFN-gamma can be promoted, so that liver cancer cells are killed. Therefore, the invention provides application guidance for accurate and effective treatment of HCC.

A method for treating eosinophilic gastritis or eosinophilic gastroenteritis is provided. In one embodiment, the method comprises administering to a subject one or more doses of an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or its antigen-binding fragment.

This invention provides multiple oligodeoxyribonucleotides (ODNs), including CpGs, that have the function of modulating the immune system of organisms, and their uses. These oligodeoxyribonucleotides differ in sequence and structure from the design concepts of conventional type A CpG ODNs, demonstrating complex drug discovery rules and solving the challenges of conventional type A CpG drug discovery. They exhibit excellent activity in modulating the immune function of organisms both in vitro and in vivo, stimulating the production of type I, II, and III interferons, enhancing the Th1 immune response, and suppressing Th2 and Th17 inflammatory responses. Therefore, they can prevent and treat allergic diseases caused by Th2 immune responses, such as allergic rhinitis, atopic dermatitis, asthma, chronic obstructive pulmonary disease, eosinophilic granulocyte and Th17-related diseases, prevent and treat infection and transmission of respiratory or non-respiratory pathogenic microorganisms such as viruses, bacteria, fungi, and parasites, and improve immune levels in elderly and immunocompromised populations. It can transform "cold tumors" into "hot tumors," improve the effectiveness of cancer immunotherapy, prevent and treat central nervous system diseases associated with immune dysregulation such as Alzheimer's disease, and can also be used for other diseases associated with immune dysregulation.

Molecules for inhibiting arachidonate 15-lipoxygenase (ALOX-15) gene products including dsRNA (dsRNA) agents such as small interfering RNAs (siRNAs) for therapeutic use, additionally, methods to inhibit the expression of a target gene by administering these agents for the treatment of diseases involving ALOX-15 gene products.

Provided herein are compositions and methods for the individualized identification of triggers allergies (e.g., non-IgE mediated allergies) in an individual. In particular, biomarkers and assays are provided and used to characterize food allergies and related conditions (e.g., food protein-induced enterocolitis syndrome (FPIES), eosinophilic esophagitis (EoE), etc.) in an individual, by identifying safe and trigger foods without the need for oral challenge.

A method of treating a tissue exhibiting eosinophil-associated inflammation in a subject is disclosed. The method comprises administering to the subject a composition comprising a therapeutically effective amount of a polymer and a pharmaceutically acceptable excipient. The polymer is formed from an acidic amino acid, such as aspartic acid and / or glutamic acid, or a pharmaceutically acceptable salt thereof. The polymer has an average molecular weight of at least about 5 kDa. The polymer binds to one or more eosinophilic granulocyte proteins in tissue to neutralize the eosinophilic granulocyte proteins and treat eosinophilic granulocyte-associated inflammation.

Disclosed are methods of diagnosing and treating a subject with active or inactive eosinophilic esophagitis (EoE). The methods may include the steps of detecting whether a level of one or more immunoglobulin antibodies is elevated in an esophageal secretion sample obtained from a subject, diagnosing the subject with active EoE when the level of one or more immunoglobulin antibodies in the sample is elevated above a pre-determined cut-off value and diagnosing the subject with inactive EoE when the level of one or more immunoglobulin antibodies level in the sample is below a pre-determined cut-off value; and treating the subject diagnosed with active EoE.

Compositions for methods for antigen specific next generation screening approaches, diagnostics, biomarkers and therapeutics for the treatment and management of eosinophilic esophagitis and other inflammatory diseases are disclosed.